Fig. 3. FGF401 demonstrates potent antitumor activity and prolongs mouse survival in high FGF19-expressing HCC models.

The efficacy of 30 mg/kg FGF401 on high and low FGF19-expressing HCC models was determined as the volume fold change relative to the vehicle control (a). Orthotopic models were established, and mice were treated with vehicle or 30 mg/kg FGF401 twice daily for 28 days. The sizes of the primary tumors (b) and Kaplan-Meier survival analyses (c, d, and e) are shown (log-rank test).